A new study shows that mutations in the GATA2 gene increase the risk of blood cancers like Myelodysplastic Syndrome and Acute Myeloid Leukemia in a more complex way than previously thought.
Instead of completely shutting down the gene, these mutations still allow some activity. However, they work unevenly—failing to support red blood cell production while continuing to drive certain white blood cells. This imbalance leads to too many granulocytes and eosinophils, and too few red blood cells and mast cells. The mutations also keep activating a factor called C/EBPε, which further pushes abnormal white blood cell growth.
The study also links these mutations to inflammation. Normally, GATA2 helps control inflammatory signals, but when it is defective, this control is lost. As a result, inflammatory activity increases. Researchers suggest that while the mutation creates a high-risk state, inflammation may act as the trigger that drives the development of leukemia.
Clinically, the findings highlight the importance of testing specific GATA2 mutations to see whether they are harmful. They also suggest that controlling inflammation could help delay or prevent leukemia in high-risk individuals. Future research will focus on how these genetic changes interact with environmental stress to drive disease progression.